Abstract
Background Sleep duration and quality has been associated with cardiovascular disease, however the effect of sleep on peripheral artery disease (PAD) specifically remains unestablished. We conducted cohort, case-control, and Mendelian randomization (MR) analyses to assess the associations of sleep duration and quality with PAD risk.
Methods Sleep traits were assessed for associations with incident PAD using cohort analysis among 53,416 Swedish adults. Replicated was sought in a case-control study of 28,123 PAD cases and 128,459 controls from the VA Million Veteran Program (MVP) and a cohort study of 452,028 individuals from the UK Biobank study (UKB). Two-sample Mendelian randomization (MR) was used for casual inference-based analyses of sleep-related traits and PAD (31,307 PAD cases 211,753 controls).
Results Observational analyses demonstrated a U-shaped association between sleep duration and PAD risk. In Swedish adults, incident PAD risk was higher in those with short sleep (<5 hours; hazard ratio (HR), 1.74; 95% confidence interval (CI) 1.31-2.31) or long sleep (≥8 hours; HR 1.24; 95% CI 1.08-1.43), compared to individuals with a sleep duration of 7 to <8 hours/night. This finding was supported by case-control analysis in MVP and cohort analysis in UKB. Observational analysis also revealed positive associations between poor sleep quality (HR, 1.81; 95% CI 1.13-2.90) and daytime napping (HR, 1.32; 95% CI 1.18-1.49) with PAD. MR analysis supported an inverse association between sleep duration (odds ratio per hour increase, 0.79, 95% CI, 0.55, 0.89) and PAD, and an association between short sleep and increased PAD (odds ratio, 1.20, 95% CI, 1.04-1.38). MR also found an association between insomnia with PAD (OR, 1.10; 95% CI 1,05-1.15) and a reverse association of PAD on shorter sleep (OR, 1.05; 95% CI 1.01-1.10).
Conclusions Maintenance of healthy sleep habits, especially avoiding habitual short sleep, may prevent PAD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study came from the Karolinska Institutet Research Foundation Grants (Grant number 2020-01842), the Swedish Research Council (Grant Number 2019-00977), the Swedish Research Council for Health, Working Life and Welfare (2018-00123) and the Swedish Heart-Lung Foundation (Grant number 20190247). M.G.L. is supported by the Institute for Translational Medicine and Therapeutics of the Perelman School of Medicine at the University of Pennsylvania and the NIH/NHLBI National Research Service Award postdoctoral fellowship (T32HL007843). S.M.D. is supported by IK2-CX001780. This publication does not represent the views of the Department of Veterans Affairs or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the Swedish Ethical Review Authority (no. 2019-03986) and the United States VA Central IRB. The UK Biobank received ethical permits from the North West Multi-centre Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. All participants have provided informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
De-identified SIMPLER data are available for researchers upon application (http://www.simpler4health.se/). Summary data from the MVP GWAS of PAD can be obtained via dbGaP Study Ascession: phs001672. Access to the UK Biobank data can be obtained upon application (https://www.ukbiobank.ac.uk/). Data used in two-sample Mendelian randomization analysis are available in Supplementary materials.
